HLA class I defects in malignant lesions: What have we learned?
The Keio Journal of Medicine · 2003 · 52 (4) · 220-229
DOI: 10.2302/kjm.52.220 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Keio Journal of Medicine, 2003. Verfasst von Chien-Chung Chang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. Die Arbeit wurde bisher 60-mal zitiert (Crossref). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Förderung
- NCI NIH HHS
Zitieren
APA
Chang, C. C., Campoli, M., & Ferrone, S. (2003). HLA class I defects in malignant lesions: What have we learned?. The Keio Journal of Medicine, 52(4), 220-229. https://doi.org/10.2302/kjm.52.220
Vancouver
Chang CC, Campoli M, Ferrone S. HLA class I defects in malignant lesions: What have we learned?. The Keio Journal of Medicine. 2003;52(4):220-229. doi:10.2302/kjm.52.220
BibTeX
@article{Chang2003,
author = {Chang, Chien-Chung and Campoli, Michael and Ferrone, Soldano},
title = {HLA class I defects in malignant lesions: What have we learned?},
journal = {The Keio Journal of Medicine},
year = {2003},
volume = {52},
number = {4},
pages = {220--229},
doi = {10.2302/kjm.52.220}
}
EUVIMED